All In Biotech

Drug Trial Radar · NCT05787418

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of HH-120 Nasal Spray for Post-exposure Prophylaxis of SARS-CoV-2

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 918 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

918

Actual

Start

Mar 31, 2023

Primary completion

Mar 27, 2024

Study completion Apr 17, 2024

Sponsor

Lead sponsor
Huahui HealthIndustry
Sponsor type
Industry
First posted
Mar 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.

Conditions

  • COVID-19

Interventions

  • HH-120 Nasal SprayDrug

    HH-120 nasal spray 8 times per day for 7 consecutive days

  • PlaceboDrug

    Placebo 8 times per day for 7 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of symptomatic SARS-CoV-2 infectionTime frame: Up to 7 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • Huashan Hospital of Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.